Drugs / SP-8356
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05574166 | Jan → Oct 2021 | atherosclerosis, ischemic stroke | Shin Poong Pharmaceutical Co. Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-27 | Shin Poong Pharmaceutical Co. Ltd. | Regulatory 난치성 심혈관질환 치료제 신약 ‘SP-8356’ 영국에서 임상 1상 승인 shinpoong.co.kr ↗
신풍제약(대표이사 유제만)은 영국의약품 및 보건의료제품규제청(MHRA)으로부터 난치성 심혈관질환 치료제 신약후보물질인 SP-8356에 대한 1상 임상시험승인(CTA)을 받았다고 26일 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-27 | Shin Poong Pharmaceutical Co. Ltd. | 난치성 심혈관질환 치료제 신약 ‘SP-8356’ 영국에서 임상 1상 승인 shinpoong.co.kr ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-8356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574166 ↗ |
| Action | Inhibit | “novel CD147 inhibitor” NCT05574166 ↗ |
| Modality | Small molecule | — CHEMBL2426707 ↗ |